# Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal

> **NCT01341496** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 41 (actual)

## Conditions studied

- Sarcoma
- Melanoma
- Epithelial Malignancies
- Pleural Malignancy

## Interventions

- **BIOLOGICAL:** Epigenetically Modified Autologous Tumor
- **DRUG:** Cyclophosphamide
- **DRUG:** Celecoxib

## Key facts

- **NCT ID:** NCT01341496
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-04-18
- **Primary completion:** 2016-05-12
- **Final completion:** 2016-07-21
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2018-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01341496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01341496, "Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01341496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*